Banking on mRNA: engineered platelets
In this issue of Blood, Strong et al1 demonstrate the compatibility of mRNA lipid nanoparticle (LNP) transfection to genetically engineer platelet componen
Related Articles
Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer
Three-dimensional invasion-linked gene expression analysis reveals a therapeutic vulnerability to inhibition of ALK2/BMP6 signaling in LKB1-mutant lung cancer that can be rapidly translated to the…
Menin inhibitors emerge as new treatment for advanced AML – The Cancer Letter
The world of cancer treatments continues to evolve, and for those diagnosed with blood cancers, a new option can be found in menin inhibitors—the latest…
Paltusotine May Address Unmet Need in NETs Patients With Carcinoid Syndrome
Paltusotine can alleviate symptoms of carcinoid syndrome in patients with neuroendocrine tumors, a phase 2 study suggests.
Mirdametinib Improves HRQOL in Adult and Pediatric Patients With NF1-PN
Mirdametinib led to sustained, significant, and clinically meaningful improvements in HRQOL in adults and children with NF1-PN.
Program: Wednesday, February 26
wednesday, february 26 continental breakfast 7-8 a.m. Keynote Session 4 8-8:30 a.m. Session Chair: Antoni Ribas, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California education…
Enhancing ctDNA monitoring for prime time use in high-risk melanoma
Meghan Mooradian, MD, Massachusetts General Hospital, Boston, MA, reviews how current research can improve circulating tumor DNA (ctDNA) monitoring before prime time use for patients…
The Targeted Pulse: Discover Key FDA Actions in Leukemia and NSCLC and The Significant Effects of TKIs in CML and CLL
The FDA grants approval to revumenib (SNDX-5613) for a subgroup of acute leukemia, and dato-dXd moves into the final stage in NSCLC. We also cover…
FDA OKs New Drug Label for Fludarabine Phosphate for CLL Treatment
The FDA approved an updated drug label for fludarabine phosphate for the treatment of B-cell chronic lymphocytic leukemia.
Understanding fibrinogen genetics
In this issue of Blood, Huffman et al1 present a multiethnic meta-analysis on fibrinogen combining whole genome-sequenced (WGS) and chip-typed individuals
Factors to consider when choosing between ‘watch and wait’ versus early intervention in SMM
Irene Ghobrial, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses factors that are important to consider when deciding whether to treat individuals with smoldering multiple…
